Pharmos Corp. announced that Israel has approved Phase Isafety studies in human volunteers of an improved submicronemulsion (SME) formulation of adaprolol maleate, a beta-blocker used for treating glaucoma.
In Phase II clinical studies, it has been shown to lowerintraocular pressure without producing any cardiovascular orrespiratory side effects.
The New York company's (NASDAQ:PARS) site-specific drugdelivery technology, SME, is aimed at increasing the safety oftreatment by reducing the drug's toxic effects. SME enableswater insoluble drugs to be formulated into uniform minutesize droplets, increasing the tissue concentration of drugs andproviding a sustained release of the drug.
(c) 1997 American Health Consultants. All rights reserved.